WL#GRAL#TS999999999 #GRAL:$138.27 | Healthcare Market Cap: 6.602B | 52-Week High: $151.46 | Live cash :$$779.09M TS 52-Week-Low-Reversal (246% Gain Since 31 Weeks) + TS WEEKLY Gems (66% gain in 2 weeks) + TS WEEKLY Uptrend (49% gain in 1 weeks) + TS ULTIMATE REPORT (Consistently shares increasing from 2 QTRS ) Main catalyst: GRAIL’s Galleri blood test received a favorable FDA advisory committee vote, significantly increasing expectations for potential FDA approval. FDA vote: Panelists voted 10–0 on safety, 6–4 on effectiveness, and 7–2, with one abstention, that benefits outweigh risks. Why approval matters: FDA approval could improve the possibility of Medicare and private-insurance coverage, potentially expanding Galleri adoption. Market opportunity: The multi-cancer early-detection market was estimated at about $1.5B in 2026 and could reach $4.6B by 2033. Key highlights : Q2 2026 Galleri revenue reached $42.6M, up 24% YoY, with more than 61,000 tests performed. GRAIL is focused on expanding Galleri adoption, regulatory approval, reimbursement opportunities, and broader cancer-screening access. Q2 2026 revenue : Total revenue was $44.7M, up 26% YoY. GRAIL reported a $110.2M net loss, showing that the company remains significantly loss-making. Cash position : GRAIL had approximately $861.6M in cash, cash equivalents and short-term marketable securities at June 30, 2026. Growth highlight : H1 2026 Galleri testing exceeded 117,000 tests, up 42% YoY, while Galleri revenue reached $82.5M, up 30% YoY. Company profile: GRAIL, Inc. is a commercial-stage healthcare company focused on early cancer detection, offering its Galleri multi-cancer early detection test and precision oncology technologies. Please always do your DD